FindTrial
Sign In

Treatment of mature B-cell lymphoma/leukaemia

Randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17584197
Enrollment
Unknown
Registered
2001-07-01
Start date
1997-01-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkins), leukaemia (acute) Cancer Lymphoma (non-Hodgkins), leukaemia (acute)

Interventions

1. Arm A: A single course of cyclophosphamide, vincristine, prednisolone (COP) followed by two courses of chemotherapy with cyclophosphamide, vincristine, prednisolone, adriamycin, hydrocortisone and

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. B-large cell, small non-cleaved non-Hodgkin's disease or B-cell leukaemia 2. Stages I-IV 3. Aged over 6 months and under 18 years 4. No previous chemotherapy. Emergency radiotherapy or immunotherapy is permitted 5. No congenital immunodeficiency 6. No prior organ transplantation 7. No previous malignancy of any type 8. No medical contraindications to protocol treatments 9. Patients available for a minimal follow-up of 36 months

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

France, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026